Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3. This reflects a minor update to the page's versioning, not a change to visible content.SummaryDifference0.1%

- Check24 days agoChange DetectedA new revision tag Revision: v3.6.2 was added, replacing the previous v3.6.0 tag.SummaryDifference0.0%

- Check31 days agoChange DetectedPublications section added with a PubMed-cited article related to the study, and a note that such publications are automatically populated from PubMed.SummaryDifference0.2%

- Check38 days agoChange DetectedEnrollment status updated to indicate recruitment is closed, signaling that the study will no longer seek new participants.SummaryDifference0.5%

- Check45 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, indicating a new version of the page. There are no visible content changes indicated by this tag.SummaryDifference0.0%

- Check52 days agoChange DetectedNo additions or deletions were provided for this page, so there are no changes to summarize. The existing content remains unchanged.SummaryDifference0.1%

Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.